citation

Julie Louise Gerberding, M.D., MPH. "Co-Chair Statement on the June 2021 Meeting of Commissioners." CSIS Commission on Strengthening America's Health Security, Center for Strategic and International Studies, July 21, 2021. Accessed December 21, 2023. https://healthsecurity.csis.org/articles/co-chair-statement-on-the-june-2021-meeting-of-commissioners/

On June 17, the CSIS Commission on Strengthening America’s Health Security convened its members and expert advisors to weigh a commission white paper that both provides an update on the global pandemic and details several concrete recommendations to strengthen U.S. international leadership.

Photo Credit: PAVEL GOLOVKIN/POOL/AFP via Getty Images

On June 17, the CSIS Commission on Strengthening America’s Health Security convened its members and expert advisors to weigh a commission white paper that both provides an update on the global pandemic and details several concrete recommendations to strengthen U.S. international leadership. Today, we are pleased to publish the white paper entitled “Time to Escalate U.S. Leadership on Covid-19 and Beyond.” It captures the majority consensus of the commissioners’ sentiments, integrating the commission’s extensive work over the past six months. In the coming days, the paper will be disseminated widely, including to Congress and within the administration. We do hope you are able to read the paper in its entirety, and we welcome your feedback.

How has the world changed?

Since early this year, a far more dangerous and uncertain phase of the pandemic has arrived that fundamentally changes the calculations of the United States and others. Variants and the egregious vaccine gap dominate the world’s attention.

At home, we have benefited enormously from the acceleration of the national vaccination campaign. That pivot towards greater control and confidence enables more U.S. international engagement. But domestic progress has slowed and remains fragile. In the meantime, the domestic and international agendas are fusing, requiring an intensified focus on what is happening both at home and abroad.

It is encouraging that the U.S. government has taken several important recent steps to demonstrate leadership in addressing the global pandemic crisis. Nonetheless, the U.S. lacks both a clear and authoritative leadership structure and a strategy to guide international action. These need to be urgent priorities.

Across the world, high-level diplomacy, largely paralyzed in 2020, is resuming, though haltingly. A strong, concerted push by the United States, led by President Biden, is the single most important element that can drive global progress forward.

Below is a summary of the commission’s recommendations to Congress and the administration.

[

Summary
Summary ](https://csis-website-prod.s3.amazonaws.com/s3fs-public/210721_Gerberding_Brooks_Statement.jpg?mpigniGWtfeAjkb9bXN_Xi5jVl6sN8Ho)

Julie Gerberding
Executive Vice President and Chief Patient Officer, Merck
Commission Co-Chair

Susan Brooks
Former U.S. Congresswoman (R-IN-5)
Commission Co-Chair

Commentary is produced by the Center for Strategic and International Studies (CSIS), a private, tax-exempt institution focusing on international public policy issues. Its research is nonpartisan and nonproprietary. CSIS does not take specific policy positions. Accordingly, all views, positions, and conclusions expressed in this publication should be understood to be solely those of the author(s).

Tags:

Next Article

A Conversation with Dr. Anthony Fauci on the Antiviral Program for Pandemics

On Tuesday, August 3rd from 2:00 p.m. – 3:00 p.m. EDT, the CSIS Commission on Strengthening America’s Health Security will host a fireside chat with Dr. Anthony Fauci, Chief Medical Advisor to the President and Director of the National Institute of Allergy and Infectious Diseases. Moderated by J. Stephen Morrison, Senior Vice President and Director of the CSIS Global Health Policy Center, the discussion will examine the administration’s signature initiative, the Antiviral Program for Pandemics, which dedicates $3.2 billion to speed development of antivirals for COVID-19 and other viruses with the potential to become pandemics.